
Cencora Inc (COR) Stock Forecast & Price Target
Cencora Inc (COR) Analyst Ratings
Bulls say
Cencora is in a strong position in the pharmaceutical wholesale industry, with a dominant market share alongside McKesson and Cardinal Health. The company's expansion into international markets through the acquisition of Alliance Healthcare in Europe provides additional growth opportunities. Despite potential regulatory challenges to drug pricing and reimbursement, its strategy to focus on specialty pharmaceuticals and vertical integration into higher-margin services should aid in navigating these headwinds.
Bears say
Cencora is primarily focused on pharmaceutical distribution to healthcare providers and lacks diversification in its growth drivers. With potential antitrust concerns and increased regulatory scrutiny on distribution economics, the company's market share and profitability may be at risk. Furthermore, customer concentration and contract renewal risks, as well as cybersecurity threats, could impact the company's revenue visibility and reputation. This negative outlook is reflected in our price target of $330 and Sector Perform rating, as we believe Cencora will face challenges in maintaining its current market share and profitability in the competitive pharmaceutical distribution industry.
This aggregate rating is based on analysts' research of Cencora Inc and is not a guaranteed prediction by Public.com or investment advice.
Cencora Inc (COR) Analyst Forecast & Price Prediction
Start investing in Cencora Inc (COR)
Order type
Buy in
Order amount
Est. shares
0 shares